<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">rpcardio</journal-id><journal-title-group><journal-title xml:lang="en">Rational Pharmacotherapy in Cardiology</journal-title><trans-title-group xml:lang="ru"><trans-title>Рациональная Фармакотерапия в Кардиологии</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1819-6446</issn><issn pub-type="epub">2225-3653</issn><publisher><publisher-name>«SILICEA-POLIGRAF» LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20996/1819-6446-2023-2934</article-id><article-id custom-type="edn" pub-id-type="custom">NKPQMO</article-id><article-id custom-type="elpub" pub-id-type="custom">rpcardio-2934</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>NOTES FROM PRACTICE</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЙ ОПЫТ</subject></subj-group></article-categories><title-group><article-title>Clinical features of heart failure in patients with atrial fibrillation: the role of the endovascular left atrial appendage closure</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности течения хронической сердечной недостаточности у пациентов с фибрилляцией предсердий: роль эндоваскулярной изоляции ушка левого предсердия</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5290-0065</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Певзнер</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Pevzner</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Певзнер Дмитрий Вольфович - руководитель отдела неотложной кардиологии</p><p>Москва</p></bio><bio xml:lang="en"><p>Dmitry V.Pevzner</p><p>Moscow</p></bio><email xlink:type="simple">pevsner@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8746-8727</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кострица</surname><given-names>Н. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kostritca</surname><given-names>N. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кострица Наталья Сергеевна </p><p>Москва</p></bio><bio xml:lang="en"><p>Natalia S.Kostritca</p><p>Moscow</p></bio><email xlink:type="simple">nataliakostritsaffm@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7461-3422</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Меркулова</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Merkulova</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Меркулова Ирина Алексеевна</p><p>Москва</p></bio><bio xml:lang="en"><p>Irina A.Merkulova</p><p>Moscow</p></bio><email xlink:type="simple">merkulova.irina579@list.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2586-4820</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Дорогун</surname><given-names>О. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Dorogun</surname><given-names>O. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Дорогун Олег Борисович</p><p>Москва</p></bio><bio xml:lang="en"><p>Oleg B.Dorogun</p><p>Moscow</p></bio><email xlink:type="simple">oleg.dorogun@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9141-103X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Комаров</surname><given-names>А. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Komarov</surname><given-names>A. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Комаров Андрей Леонидович - ведущий научный сотрудник отдела атеротромбоза</p><p>Москва</p></bio><bio xml:lang="en"><p>Andrei L.Komarov</p><p>Moscow</p></bio><email xlink:type="simple">andrkomarov@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2816-1183</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Явелов</surname><given-names>И. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Yavelov</surname><given-names>I. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Явелов Игорь Семенович- руководитель отдела фундаментальных и клинических проблем тромбоза при неинфекционных заболеваниях, заместитель председателя секции "Неотложная кардиология" РКО, д.м.н., профессор</p><p>Москва</p></bio><bio xml:lang="en"><p>Igor S.Yavelov</p><p>Moscow</p></bio><email xlink:type="simple">yavelov@yahoo.com</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>E.I. Chazov National Medical Research Center of Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Medical Research Centre for Therapy and Preventive Medicine</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2023</year></pub-date><pub-date pub-type="epub"><day>29</day><month>08</month><year>2023</year></pub-date><volume>19</volume><issue>4</issue><fpage>350</fpage><lpage>358</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Pevzner D.V., Kostritca N.S., Merkulova I.A., Dorogun O.B., Komarov A.L., Yavelov I.S., 2023</copyright-statement><copyright-year>2023</copyright-year><copyright-holder xml:lang="ru">Певзнер Д.В., Кострица Н.С., Меркулова И.А., Дорогун О.Б., Комаров А.Л., Явелов И.С.</copyright-holder><copyright-holder xml:lang="en">Pevzner D.V., Kostritca N.S., Merkulova I.A., Dorogun O.B., Komarov A.L., Yavelov I.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpcardio.online/jour/article/view/2934">https://www.rpcardio.online/jour/article/view/2934</self-uri><abstract><sec><title>Aim</title><p>Aim. To evaluate the long-term impact of endovascular left atrial appendage occlusion (LAAO) on heart failure (HF) course in patients with atrial fibrillation (AF).</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods: The prospective cohort study included patients with AF, HF, and a high risk of thromboembolic events, of which 39,6% underwent LAAO, 60,4% — received standard preventive therapy for cardioembolic events. Changes in BNP levels in the LAAO and control groups were analyzed throughout the observation period. The incidence of unfavorable HF outcomes (decompensated HF, hospitalizations related to HF, worsening HF class) was compared using the Cox-regression analysis with the log-rank test. A univariate analysis using Cox regression was conducted to identify independent predictors of endpoint achievement, involving all clinical and historical factors. Subsequently, a multivariate analysis was carried out, with predictors selected through the Wald exclusion test from those factors with a p-value less than 0.2 in the univariate analysis. Each factor was found to be a statistically significant independent predictor of the endpoint, with the overall model significance of p&lt;0,001</p></sec><sec><title>Results</title><p>Results: s. The study included 139 patients (55 — LAAO group; 84 — control group) with a 3-year follow-up period. Most patients in the study had class I-III HF with preserved left ventricular ejection fraction (93,5%). In both groups, the level of BNP increased significantly over the observational period. Despite the initial differences between the groups, no differences were observed between the groups 1-3 years after the start of the study, which may indicate a tendency towards a lower growth rate of BNP in the LAAO group. The achievement rate of all endpoints was similar in both groups without significant differences. Multivariate analysis identified significant predictors of HF decompensation in the study cohort including left atrial volume, BNP levels, and HF class.</p></sec><sec><title>Conclusion</title><p>Conclusion. Our study hasn’t shown any negative impact of endovascular LAAO on HF course in patients with AF. Additionally, several predictors of HF decompensation were identified in this patient cohort. </p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Цель</title><p>Цель: оценка связи эндоваскулярной изоляции УЛП с течением ХСН у пациентов с ФП в отдаленном периоде.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы: в проспективное когортное исследование включались пациенты с ФП, ХСН и высоким риском тромбоэмболических осложнений, части из которых была выполнена имплантация окклюдера УЛП, остальным – проводилась стандартная профилактика кардиоэмболических осложнений. Сравнение частоты конечных точек неблагоприятного течения ХСН (декомпенсации ХСН, госпитализации, связанные с ХСН, увеличение функциональный класс ХСН) проводилось методом регрессионного анализа с помощью критерия log-rank. Для выявления независимых предикторов достижения конечных точек проводился однофакторный анализ методом регрессии Кокса с вовлечением всех клинико-анамнестических факторов. Далее проводился многофакторный анализ, отбор предикторов в котором проводился методом исключения Вальда из тех факторов, для которых значение р в однофакторном анализе было менее 0,2. Каждый из факторов был статистически значимым независимым предиктором конечной точки, общая значимость модели составила р &lt;0,001</p></sec><sec><title>Результаты</title><p>Результаты. В исследование были включены 139 пациентов (55 пациентов в группу окклюдера, 84 — в группу контроля), период наблюдения составил 3 года. Преимущественно у пациентов в исследовании была диагностирована ХСН с сохранной фракцией выброса левого желудочка (93,5% случаев) I-III функционального класса. В обеих группах за время наблюдения уровень BNP статистически значимо увеличился. Несмотря на наличие исходных различий между группами, через 1-3 года после начала исследования различий между группами не отмечалось, что может свидетельствовать о тенденции к меньшему росту уровня BNP в группе окклюдера. Частота достижения всех конечных точек была сходной в обеих группах, статистически значимых различий выявлено не было. При многофакторном анализе были выявлены статистически значимые предикторы декомпенсации ХСН в исследуемой когорте: объём левого предсердия, уровень BNP, функционального класса ХСН.</p></sec><sec><title>Заключение</title><p>Заключение. Не было выявлено негативного влияния эндоваскулярной окклюзии УЛП на течение ХСН у пациентов с ФП. Кроме того, был выявлен ряд предикторов декомпенсации ХСН в данной когорте пациентов.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>фибрилляция предсердий</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>окклюдер ушка левого предсердия</kwd><kwd>кардиоэмболические осложнения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>atrial fibrillation</kwd><kwd>chronic heart failure</kwd><kwd>left atrial appendage occlude</kwd><kwd>cardioembolic events</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Исследование проведено при поддержке ФГБУ Национальный медицинский исследовательский центр кардиологии имени академика Е.И. Чазова Министерства здравоохранения Российской Федерации</funding-statement><funding-statement xml:lang="en">The study was performed with the support of Federal State Budgetary Institution National Medical Research Centre of Cardiology named after academician E. I. Chazov of the Ministry of Health of the Russian Federation.</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Reddy YNV, Borlaug BA, Gersh BJ. Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation. 2022;146(4):339-57. DOI:10.1161/CIRCULATIONAHA.122.057444.</mixed-citation><mixed-citation xml:lang="en">Reddy YNV, Borlaug BA, Gersh BJ. Management of Atrial Fibrillation Across the Spectrum of Heart Failure With Preserved and Reduced Ejection Fraction. Circulation. 2022;146(4):339-57. DOI:10.1161/CIRCULATIONAHA.122.057444.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Karnik AA, Gopal DM, Ko D, et al. Epidemiology of Atrial Fibrillation and Heart Failure. Cardiol Clin. 2019;37(2):119-29. DOI:10.1016/j.ccl.2019.01.001.</mixed-citation><mixed-citation xml:lang="en">Karnik AA, Gopal DM, Ko D, et al. Epidemiology of Atrial Fibrillation and Heart Failure. Cardiol Clin. 2019;37(2):119-29. DOI:10.1016/j.ccl.2019.01.001.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ariyaratnam JP, Lau DH, Sanders P, Kalman JM. Atrial Fibrillation and Heart Failure. Card Electrophysiol Clin. 2021;13(1):47-62. DOI:10.1016/j.ccep.2020.11.004.</mixed-citation><mixed-citation xml:lang="en">Ariyaratnam JP, Lau DH, Sanders P, Kalman JM. Atrial Fibrillation and Heart Failure. Card Electrophysiol Clin. 2021;13(1):47-62. DOI:10.1016/j.ccep.2020.11.004.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Chamberlain AM, Redfield MM, Alonso A, et al. Atrial Fibrillation and Mortality in Heart Failure: A Community Study. Circ Heart Fail. 2011;4(6):740-6. DOI:10.1161/ CIRCHEARTFAILURE.111.962688.</mixed-citation><mixed-citation xml:lang="en">Chamberlain AM, Redfield MM, Alonso A, et al. Atrial Fibrillation and Mortality in Heart Failure: A Community Study. Circ Heart Fail. 2011;4(6):740-6. DOI:10.1161/ CIRCHEARTFAILURE.111.962688.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Аракелян М. Г., Бокерия Л.А., Васильева Е.Ю., и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. DOI:10.15829/1560-4071-2021-4594.</mixed-citation><mixed-citation xml:lang="en">Arakelyan MG, Bockeria LA, Vasilieva EYu, et al. 2020 Clinical guidelines for Atrial fibrillation and atrial flutter. Russ. J.Cardiol. 2021;26(7):4594 (In Russ.) DOI:10.15829/1560-4071-2021-4594.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599- 726. DOI:10.1093/eurheartj/ehab368.</mixed-citation><mixed-citation xml:lang="en">McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599- 726. DOI:10.1093/eurheartj/ehab368.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Cruz-Gonzalez I, Palazuelos Molinero J, Valenzuela M, et al. Brain natriuretic peptide levels variation after left atrial appendage occlusion: BNP and Left Atrial Appendage Occlusion. Catheter Cardiovasc Interv. 2016;87(1):E39-43. DOI:10.1002/ccd.25985.</mixed-citation><mixed-citation xml:lang="en">Cruz-Gonzalez I, Palazuelos Molinero J, Valenzuela M, et al. Brain natriuretic peptide levels variation after left atrial appendage occlusion: BNP and Left Atrial Appendage Occlusion. Catheter Cardiovasc Interv. 2016;87(1):E39-43. DOI:10.1002/ccd.25985.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. DOI:10.1136/bmj.i4482.</mixed-citation><mixed-citation xml:lang="en">Odutayo A, Wong CX, Hsiao AJ, et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ. 2016;354:i4482. DOI:10.1136/bmj.i4482.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vigna C, Russo A, De Rito V, et al. Frequency of left atrial thrombi by transesophageal echocardiography in idiopathic and in ischemic dilated cardiomyopathy. Am J Cardiol. 1992;70(18):1500-1. DOI:10.1016/0002- 9149(92)90310-U.</mixed-citation><mixed-citation xml:lang="en">Vigna C, Russo A, De Rito V, et al. Frequency of left atrial thrombi by transesophageal echocardiography in idiopathic and in ischemic dilated cardiomyopathy. Am J Cardiol. 1992;70(18):1500-1. DOI:10.1016/0002- 9149(92)90310-U.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wiese S, Breyer T, Dragu A, et al. Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium: Influence of Angiotensin II and Diastolic Fiber Length. Circulation. 2000;102(25):3074-9. DOI:10.1161/01. CIR.102.25.3074.</mixed-citation><mixed-citation xml:lang="en">Wiese S, Breyer T, Dragu A, et al. Gene Expression of Brain Natriuretic Peptide in Isolated Atrial and Ventricular Human Myocardium: Influence of Angiotensin II and Diastolic Fiber Length. Circulation. 2000;102(25):3074-9. DOI:10.1161/01. CIR.102.25.3074.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37(5):1221-7. DOI:10.1016/S0735-1097(01)01172-X.</mixed-citation><mixed-citation xml:lang="en">Brunner-La Rocca HP, Kaye DM, Woods RL, et al. Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol. 2001;37(5):1221-7. DOI:10.1016/S0735-1097(01)01172-X.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) Trial. Am Heart J. 2006;151(5):956-61. DOI:10.1016/j.ahj.2006.02.005.</mixed-citation><mixed-citation xml:lang="en">Fountain RB, Holmes DR, Chandrasekaran K, et al. The PROTECT AF (WATCHMAN Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation) Trial. Am Heart J. 2006;151(5):956-61. DOI:10.1016/j.ahj.2006.02.005.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Holmes DR, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. J Am Coll Cardiol. 2014;64(1):1- 12. DOI:10.1016/j.jacc.2014.04.029.</mixed-citation><mixed-citation xml:lang="en">Holmes DR, Kar S, Price MJ, et al. Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy. J Am Coll Cardiol. 2014;64(1):1- 12. DOI:10.1016/j.jacc.2014.04.029.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kim D-Y, Kim M, Seo J, et al. Predictors of Subsequent Heart Failure After Left Atrial Appendage Closure. Circ J. 2022;86(7):1129-1136. DOI:10.1253/circj.CJ-21- 0642.</mixed-citation><mixed-citation xml:lang="en">Kim D-Y, Kim M, Seo J, et al. Predictors of Subsequent Heart Failure After Left Atrial Appendage Closure. Circ J. 2022;86(7):1129-1136. DOI:10.1253/circj.CJ-21- 0642.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Szymala M, Streb W, Mitrega K, et al. Percutaneous left atrial appendage occlusion procedures in patients with heart failure. Kardiol Pol.2017;75(9):868- 876. DOI:10.5603/KP.a2017.0115.</mixed-citation><mixed-citation xml:lang="en">Szymala M, Streb W, Mitrega K, et al. Percutaneous left atrial appendage occlusion procedures in patients with heart failure. Kardiol Pol.2017;75(9):868- 876. DOI:10.5603/KP.a2017.0115.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gorriz Magana J, Abad Romero R, Nieto Ibanez D, et al. Predictors of Acute Heart Failure Decompensation at 30 days After Discharge. Results from a Multidisciplinary Heart Failure unit. Eur Heart J. 2021;42. DOI:10.1093/ eurheartj/ehab724.1042.</mixed-citation><mixed-citation xml:lang="en">Gorriz Magana J, Abad Romero R, Nieto Ibanez D, et al. Predictors of Acute Heart Failure Decompensation at 30 days After Discharge. Results from a Multidisciplinary Heart Failure unit. Eur Heart J. 2021;42. DOI:10.1093/ eurheartj/ehab724.1042.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Sarteschi C, Viera De Souza W, Medeiros C, et al. Predictors of Post-Discharge 30-Day Hospital Readmission in Decompensated Heart Failure Patients. Int J Cardiovasc Sci. 2020; 33(2):175-184. DOI:10.36660/ijcs.20180088</mixed-citation><mixed-citation xml:lang="en">Sarteschi C, Viera De Souza W, Medeiros C, et al. Predictors of Post-Discharge 30-Day Hospital Readmission in Decompensated Heart Failure Patients. Int J Cardiovasc Sci. 2020; 33(2):175-184. DOI:10.36660/ijcs.20180088</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Baldasseroni S, Virciglio S, Herbst A, et al. Predictors of 1-year outcome in very old patients managed in a Heart Failure Unit after an acute decompensation. Eur Geriatr Med. 2022;13(6):1417-24. DOI:10.1007/s41999-022-00679-5.</mixed-citation><mixed-citation xml:lang="en">Baldasseroni S, Virciglio S, Herbst A, et al. Predictors of 1-year outcome in very old patients managed in a Heart Failure Unit after an acute decompensation. Eur Geriatr Med. 2022;13(6):1417-24. DOI:10.1007/s41999-022-00679-5.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
